- Home
- BLRX vs AIMD Comparison
BLRX vs AIMD Comparison
Compare BLRX & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLRX | AIMD |
|---|---|---|
| Founded | 2003 | 1984 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 10.2M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLRX | AIMD |
|---|---|---|
| Price | $2.93 | $1.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | 23.2K | ★ 24.7K |
| Earning Date | 11-24-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,735,000.00 | $113,037.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 178.19 |
| 52 Week Low | $2.30 | $1.78 |
| 52 Week High | $14.70 | $5.00 |
Technical Indicators
Market Signals| Indicator | BLRX | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 37.19 |
| Support Level | $2.85 | $1.94 |
| Resistance Level | $3.03 | $2.18 |
| Average True Range (ATR) | 0.17 | 0.12 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 18.39 | 6.28 |
Price Performance
Historical ComparisonAbout BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About AIMD Ainos Inc.
Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.